ALT A groundbreaking stem cell nerve therapy has officially entered human trials to reverse paralysis caused by spinal cord injuries. The treatment, called XS228, uses lab-grown neurons derived from induced pluripotent stem cells (iPSCs). These cells are reprogrammed from adult donors and transformed into neural precursors capable of regenerating damaged spinal tissue. In preclinical studies, the therapy helped paralyzed animals regain movement by growing new axons and forming connections with host nerve cells. Now, researchers in China have launched the world’s first registrational trial to test its safety and effectiveness in humans. If successful, this could be a game-changer, offering a scalable, off-the-shelf solution to restore mobility and independence for millions affected by spinal cord injuries. This marks a historic step in regenerative medicine, offering new hope to the millions living with spinal cord injuries worldwide.